Results of the present study demonstrate that Storax alleviates brain injury of cerebral ischemia rats at 24 h after stroke, inhibits Albumin-Alexa594 leakage from BBB to the brain parenchyma, and attenuates the ultrastructural disruption of BBB at 6 h after stroke. Here, ALB is linked to stroke disorder.